The ALDOB protein level has been suggested as a biomarker for predicting postoperative prognosis in CRC patients, as well as the risk of colon cancer liver metastases and the response of rectal cancer patients to neoadjuvant chemoradiation therapy [19–21]. This evidence concerns the gene ALDOB and colonic neoplasm.